Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment
Age was associated with reduced risk of an irAE-related hospitalization but not acute care use, while increasing frailty was associated acute care use, but not irAE-related hospitalization. Age and frailty may need to be considered independently when evaluating their impact on toxicity among older adults receiving ICIs.
Authors
- Jeffrey M. Peppercorn (ORCID: https://orcid.org/0000-0001-7138-6404)
- Ning Liu (ORCID: https://orcid.org/0000-0001-7895-1285)
- Melanie Powis (ORCID: https://orcid.org/0000-0001-6038-0701)
- Yue Niu
- Shabbir MH Alibhai
- Y. Liu
- Elizabeth Faour
- M. K. Krzyzanowska
- Yosuf Kaliwal
- Rinku Sutradhar
- Lawson Eng
- Geoffrey Liu
Institutions
- University Health Network (CA)
- 3M (United States) (US)
- University of Toronto (CA)
- Toronto General Hospital (CA)
- Princess Margaret Cancer Centre (CA)
- Massachusetts General Hospital (US)
- Institute of Health Services and Policy Research (CA)
- Institute for Clinical Evaluative Sciences (CA)
- Institute for Work & Health (CA)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1093/jnci/djaf373
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00